NASDAQ:PRVB

Provention Bio Competitors

$8.11
+0.03 (+0.37 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.88
Now: $8.11
$8.20
50-Day Range
$7.76
MA: $11.36
$14.13
52-Week Range
$6.36
Now: $8.11
$20.05
Volume1.03 million shs
Average Volume1.38 million shs
Market Capitalization$513.97 million
P/E RatioN/A
Dividend YieldN/A
Beta3.34

Competitors

Provention Bio (NASDAQ:PRVB) Vs. NGM, MDGL, AXSM, AMRN, RVNC, and IGMS

Should you be buying PRVB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Provention Bio, including NGM Biopharmaceuticals (NGM), Madrigal Pharmaceuticals (MDGL), Axsome Therapeutics (AXSM), Amarin (AMRN), Revance Therapeutics (RVNC), and IGM Biosciences (IGMS).

NGM Biopharmaceuticals (NASDAQ:NGM) and Provention Bio (NASDAQ:PRVB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares NGM Biopharmaceuticals and Provention Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million19.37$-42,790,000.00($0.85)-30.76
Provention BioN/AN/A$-43,280,000.00($1.06)-7.65

NGM Biopharmaceuticals has higher revenue and earnings than Provention Bio. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Provention Bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NGM Biopharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, meaning that its share price is 234% more volatile than the S&P 500.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 39.4% of Provention Bio shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by company insiders. Comparatively, 14.4% of Provention Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares NGM Biopharmaceuticals and Provention Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
Provention BioN/A-67.66%-62.27%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for NGM Biopharmaceuticals and Provention Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
Provention Bio01502.83

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, suggesting a potential upside of 49.56%. Provention Bio has a consensus target price of $19.75, suggesting a potential upside of 143.53%. Given Provention Bio's higher probable upside, analysts clearly believe Provention Bio is more favorable than NGM Biopharmaceuticals.

Summary

NGM Biopharmaceuticals beats Provention Bio on 9 of the 13 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Provention Bio (NASDAQ:PRVB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Madrigal Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, meaning that its share price is 234% more volatile than the S&P 500.

Profitability

This table compares Madrigal Pharmaceuticals and Provention Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Madrigal PharmaceuticalsN/A-47.64%-43.21%
Provention BioN/A-67.66%-62.27%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Madrigal Pharmaceuticals and Provention Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Madrigal Pharmaceuticals03702.70
Provention Bio01502.83

Madrigal Pharmaceuticals presently has a consensus target price of $167.60, suggesting a potential upside of 34.33%. Provention Bio has a consensus target price of $19.75, suggesting a potential upside of 143.53%. Given Provention Bio's stronger consensus rating and higher probable upside, analysts clearly believe Provention Bio is more favorable than Madrigal Pharmaceuticals.

Earnings & Valuation

This table compares Madrigal Pharmaceuticals and Provention Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-22.89
Provention BioN/AN/A$-43,280,000.00($1.06)-7.65

Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Provention Bio, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.4% of Provention Bio shares are owned by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 14.4% of Provention Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Provention Bio beats Madrigal Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Provention Bio (NASDAQ:PRVB) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500.

Profitability

This table compares Provention Bio and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Provention BioN/A-67.66%-62.27%
Axsome TherapeuticsN/A-62.33%-47.87%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Provention Bio and Axsome Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Provention Bio01502.83
Axsome Therapeutics101002.82

Provention Bio currently has a consensus price target of $19.75, suggesting a potential upside of 143.53%. Axsome Therapeutics has a consensus price target of $152.6667, suggesting a potential upside of 185.68%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Provention Bio.

Earnings and Valuation

This table compares Provention Bio and Axsome Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Provention BioN/AN/A$-43,280,000.00($1.06)-7.65
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.59

Axsome Therapeutics is trading at a lower price-to-earnings ratio than Provention Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

39.4% of Provention Bio shares are owned by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are owned by institutional investors. 14.4% of Provention Bio shares are owned by insiders. Comparatively, 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Axsome Therapeutics beats Provention Bio on 6 of the 11 factors compared between the two stocks.

Provention Bio (NASDAQ:PRVB) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.58, suggesting that its stock price is 158% more volatile than the S&P 500.

Profitability

This table compares Provention Bio and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Provention BioN/A-67.66%-62.27%
Amarin-2.69%-2.70%-1.72%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Provention Bio and Amarin, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Provention Bio01502.83
Amarin03802.73

Provention Bio currently has a consensus price target of $19.75, suggesting a potential upside of 143.53%. Amarin has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. Given Provention Bio's stronger consensus rating and higher probable upside, analysts clearly believe Provention Bio is more favorable than Amarin.

Earnings and Valuation

This table compares Provention Bio and Amarin's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Provention BioN/AN/A$-43,280,000.00($1.06)-7.65
Amarin$429.76 million4.60$-22,650,000.00($0.07)-71.71

Amarin has higher revenue and earnings than Provention Bio. Amarin is trading at a lower price-to-earnings ratio than Provention Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

39.4% of Provention Bio shares are owned by institutional investors. Comparatively, 37.8% of Amarin shares are owned by institutional investors. 14.4% of Provention Bio shares are owned by insiders. Comparatively, 2.8% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Provention Bio beats Amarin on 7 of the 13 factors compared between the two stocks.

Provention Bio (NASDAQ:PRVB) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Profitability

This table compares Provention Bio and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Provention BioN/A-67.66%-62.27%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Provention Bio and Revance Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Provention Bio01502.83
Revance Therapeutics00403.00

Provention Bio currently has a consensus price target of $19.75, suggesting a potential upside of 143.53%. Revance Therapeutics has a consensus price target of $37.75, suggesting a potential upside of 38.68%. Given Provention Bio's higher probable upside, analysts clearly believe Provention Bio is more favorable than Revance Therapeutics.

Earnings and Valuation

This table compares Provention Bio and Revance Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Provention BioN/AN/A$-43,280,000.00($1.06)-7.65
Revance Therapeutics$410,000.004,739.13$-159,430,000.00($3.67)-7.42

Provention Bio has higher earnings, but lower revenue than Revance Therapeutics. Provention Bio is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

39.4% of Provention Bio shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 14.4% of Provention Bio shares are owned by insiders. Comparatively, 4.8% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Provention Bio beats Revance Therapeutics on 9 of the 13 factors compared between the two stocks.

Provention Bio (NASDAQ:PRVB) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, suggesting that its stock price is 212% less volatile than the S&P 500.

Profitability

This table compares Provention Bio and IGM Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Provention BioN/A-67.66%-62.27%
IGM BiosciencesN/A-33.30%-30.28%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Provention Bio and IGM Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Provention Bio01502.83
IGM Biosciences01602.86

Provention Bio currently has a consensus price target of $19.75, suggesting a potential upside of 143.53%. IGM Biosciences has a consensus price target of $98.8750, suggesting a potential upside of 65.65%. Given Provention Bio's higher probable upside, analysts clearly believe Provention Bio is more favorable than IGM Biosciences.

Earnings and Valuation

This table compares Provention Bio and IGM Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Provention BioN/AN/A$-43,280,000.00($1.06)-7.65
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-12.44

IGM Biosciences is trading at a lower price-to-earnings ratio than Provention Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

39.4% of Provention Bio shares are owned by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are owned by institutional investors. 14.4% of Provention Bio shares are owned by insiders. Comparatively, 79.3% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

IGM Biosciences beats Provention Bio on 7 of the 11 factors compared between the two stocks.


Provention Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15+0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77+1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44+1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02+0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22+3.5%$1.94 billion$410,000.00-5.92Analyst Report
Gap Down
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69+4.6%$1.91 billionN/A-25.40Increase in Short Interest
Gap Down
MacroGenics logo
MGNX
MacroGenics
1.2$31.83+2.4%$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73+3.2%$1.90 billion$34.51 million-17.72
Kura Oncology logo
KURA
Kura Oncology
1.6$28.59+3.1%$1.89 billionN/A-17.54
FibroGen logo
FGEN
FibroGen
1.8$19.91+3.1%$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
News Coverage
MORF
Morphic
1.3$55.08+0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70+0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89+0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61+2.2%$1.71 billion$428.41 million15.38News Coverage
Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70+0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06+1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87+0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29+1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15+0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30+2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35+2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07+4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95+4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52+2.4%$1.50 billion$82.27 million-18.34Gap Down
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24+5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84+3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14+2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37+0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26+3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51+0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71+1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56+0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38+0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85+0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68+1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
Gap Down
ATBPD
Antibe Therapeutics
0.1$3.57+0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52+4.2%$1.38 billionN/A-2.98Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67+12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35+0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01+5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68+1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99+1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89+1.6%$1.21 billion$4.23 million-8.88Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56+0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90+0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16+1.7%$1.17 billion$59.70 million-191.60Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55+0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01+0.0%$1.16 billionN/A-2.65
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.